Capitalizing on Cellular Therapies in Lymphoma and Myeloma
In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.
Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we passed the mic to Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, who moderated a discussion on cellular therapies in lymphoma and multiple myeloma with Anita D’Souza, MD, an associate professor at the Medical College of Wisconsin, and Bhagirathbhai Dholaria, MBBS, an assistant professor of medicine in the Department of Medicine at Vanderbilt University Medical Center.
In our exclusive interview, Kansagra, D’Souza, and Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.
